---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-180754"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-07-18T23:59:59+00:00"
generated_at: "2026-05-31T19:52:51.465911+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam appoints McKenna and Joustra to board; Slootweg resigns

## Summary
- Sander Slootweg resigned from the Board effective July 16, 2024; no disagreement cited.
- Wouter Joustra (Forbion general partner) and Mark C. McKenna (Mirador CEO) appointed as temporary non-executive directors.
- McKenna granted options for 72,500 ordinary shares at $18.81 per share, vesting over 3 years.
- McKenna also joins audit and compensation committees; Joustra brings capital markets and venture experience.
- Appointments effective immediately; formal ratification expected at next annual general meeting.

## SEC filing metadata
- accession: 0001193125-24-180754
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-07-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524180754/0001193125-24-180754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524180754/d744813d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-180754
- JSON: https://secwatch.observer/filing/0001193125-24-180754.json
- Plain text: https://secwatch.observer/filing/0001193125-24-180754.txt

## Key facts
- Executive change
  Sander Slootweg resigned as Director at NewAmsterdam Pharma Co N.V..
  - Action: resigned
  - Role: Director
  source text: On July 16, 2024, Sander Slootweg notified NewAmsterdam Pharma Company N.V. (the “Company”) of his decision to resign as a member of the Company’s board of directors (the “Board”) effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1936258/000119312524180754/0001193125-24-180754-index.htm
- Executive change
  Wouter Joustra was appointed as Director at NewAmsterdam Pharma Co N.V..
  - Action: appointed
  - Role: Director
  source text: On July 16, 2024, the Board appointed Wouter Joustra and Mark C. McKenna to serve as members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1936258/000119312524180754/0001193125-24-180754-index.htm
- Executive change
  Mark C. McKenna was appointed as Director at NewAmsterdam Pharma Co N.V..
  - Action: appointed
  - Role: Director
  source text: On July 16, 2024, the Board appointed Wouter Joustra and Mark C. McKenna to serve as members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1936258/000119312524180754/0001193125-24-180754-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.